pyrrolidonecarboxylic acid has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bischoff, R; de Boer, RA; Gil, A; Grote Beverborg, N; Hoendermis, ES; Schouten, EM; Silljé, HHW; Tromp, J; van der Meer, P; van der Pol, A; van Veldhuisen, DJ; Voors, AA | 1 |
| Keceli, G; Lindsey, ML; Paolocci, N; Sourdon, J | 1 |
2 other study(ies) available for pyrrolidonecarboxylic acid and Cirrhosis
| Article | Year |
|---|---|
OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Animals; Case-Control Studies; Disease Models, Animal; Female; Fibrosis; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Myocardial Reperfusion Injury; Myocardium; Oxidative Stress; Phenotype; Pyroglutamate Hydrolase; Pyrrolidonecarboxylic Acid; Randomized Controlled Trials as Topic; Signal Transduction; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2018 |
Death of an antioxidant brings heart failure with preserved ejection fraction to life: 5-oxoproline and post-ischaemic cardio-renal dysfunction.
Topics: Animals; Antioxidants; Disease Models, Animal; Fibrosis; Heart Failure; Kidney Diseases; Mice; Oxidative Stress; Pyrrolidonecarboxylic Acid; Stroke Volume | 2018 |